ADTRAN
11.3.2024 14:02:25 CET | Business Wire | Press release
Adtran today announced that Netnod is leveraging its optical pumping cesium atomic clock technology to bring precise, reliable and assured timing to Sweden’s critical national infrastructure. Protecting the country’s timing services is vital for the nation’s economy, encompassing finance, digital services and next-generation telecoms networks, such as 5G. By upgrading its timing network with the coreSync™ OSA 3300-HP, Netnod, the leading provider of internet exchange, DNS and time services in the Nordics, is enhancing the accuracy, stability and longevity of synchronization services across the region. The solution meets the need for precise timing, supporting the smooth operation and evolution of digital applications and services. It represents a significant advancement in timing that enhances Sweden’s position in digital innovation and cybersecurity.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240311684053/en/
Netnod is using Adtran’s synchronization technology for ultra-precise and reliable timing across Sweden’s national critical infrastructure. (Photo: Business Wire)
“At Netnod, we’re committed to providing the market’s most advanced and reliable timing solutions. Our new Time Direct and Remote services, built on the latest timing standards and security protocols, underscore our leadership in this domain. The deployment of Adtran’s coreSync™ OSA 3300-HP is key for providing reliable, continuous timing for Sweden’s critical infrastructure. It enhances our NTP/PTP services and strengthens Sweden’s digital backbone for essential sectors, including 5G. It also provides the country with the benefits of highly precise synchronization resilient against GNSS vulnerabilities and enables us to deliver more valuable SLAs for our customers,” said Karin Ahl, CEO of Netnod. “This upgrade is about securing the digital backbone of our nation against GNSS cyber threats, generating economic growth and reinforcing our commitment to maintaining Sweden as a leader in digital innovation and infrastructure resilience.”
Netnod is integrating Oscilloquartz super ePRC technology across six key timing centers nationwide, including the coreSync™ OSA 3300-HP, for unprecedented reliability and accuracy. The upgrade is particularly crucial for timing service assurance within a secure environment. Given the increasing vulnerabilities of GNSS, the optically pumped cesium technology offers a highly stable and accurate alternative timing source. The coreSync™ OSA 3300-HP sets new standards with its higher frequency stability and lifespan that is twice as long as traditional magnetic clocks. Its robust design is complemented by a user-friendly LCD touchscreen and Ethernet connectivity, facilitating both local and remote configuration and management. This blend of advanced features enhances time synchronization across Sweden and prepares the nation’s infrastructure for future challenges.
“Netnod is a major hub for ICT and multimedia, serving as the gateway to the Nordics’ global digital arena. Leveraging our coreSync™ OSA 3300, it’s fortifying Sweden’s critical national infrastructure, ensuring seamless operations and growth for internet service providers, content delivery networks and businesses in one of Europe’s most dynamic digital markets,” commented Stuart Broome, GM of EMEA sales at Adtran. “With our technology, Netnod can utilize multiple timing sources, enabling a zero-trust environment for clients in next-gen telecoms, finance, utilities, broadcast and beyond. This will help equip enterprises and institutions across the region with top-tier internet speed, resilience and connectivity and solidify Netnod’s position as the digital cornerstone of the Nordics.”
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
About Netnod
Netnod provides critical infrastructure support ranging from interconnection services and Internet Exchanges to time services, DNS services and root server operations. With a worldwide reputation for its services and the expertise of its staff, Netnod ensures a stable and secure Internet for the Nordics and beyond. Established in 1996 as a neutral and independent Internet infrastructure organisation, Netnod is fully owned by the non-profit foundation TU-stiftelsen (Stiftelsen för Telematikens utveckling). More information is available at: www.netnod.se.
Published by
ADTRAN Holdings, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240311684053/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom